Molly Burich, MS, associate director of public policy: biosimilars, pipeline, and reimbursement at Boehringer Ingelheim, discusses current FDA guidance on the naming and labeling of biosimilar treatments.
Transcript:
What impact does current guidance on naming and labeling have on prescribing biosimilars?
I think we’re very thankful that the FDA has released draft guidance on labeling and finalized its naming guidance. These are both important steps. The labels and the names in many ways are how patients and physicians know the product and learn the product, and for physicians how they understand the clinical data behind it.
In terms of labeling, we support that the label should look very similar to the reference product. After all, these are biosimilars to the reference product, so we believe that those labels should look very similar and are pleased with the direction the FDA seems to be taking in labeling. As it pertains to naming, the FDA did end up finalizing the use of a four-digit suffix that is devoid of meaning. I think this is a little bit challenging and this result was not what a lot of stakeholders, including some biosimilar manufacturers, wanted to see. I think we would have preferred that a suffix, if it’s needed, has to be meaningful so that doctors and patients, if needed, can remember it and it’s attributed to the manufacturer.
Unfortunately, that isn’t the way the agency went. So, that’s another opportunity for education to make sure that physicians know our suffix, know that it’s devoid of meaning as much as they can remember it, and that patients certainly understand that while there is a suffix that differentiates it, it doesn’t mean the product is any less safe or efficacious.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.